Skip to main content

Paper: Chemical, Target, and Bioactive Properties of Allosteric Modulation


We have just had a paper accepted in PLoS Computational Biology on the work we've done on allosteric modulators (first mentioned on the blog here).  The work is based on the mining of allosteric bioactivity points from ChEMBL_14. The data set of allosteric and non-allosteric interactions is available on our FTP site (here). This blogpost will just highlight some sections of the paper, but we would like to refer the interested reader to the full paper (here). 

Dataset
The dataset contains ChEMBL annotated and cleaned data divided in both an 'allosteric' set and a 'non-allosteric' (or background) set. Abstracts and titles mentioning allosteric keywords were pulled and from the resulting papers we extracted the primary target and all bioactivities on this primary target. From the remainder of the papers we also retrieved the primary target and all bioactivities on this primary target in a similar manner. 

Targets
When we observed the target distribution in both sets, we saw differences (see below ; also touched upon in the previous post). Targets that are known to be amenable to allosteric modulation are indeed well represented in our allosteric set (e.g. Class C GPCRs). However there are also some interesting observations that we did not expect (please see the paper for further details). 



Chemistry
Obviously, as we are the ChEMBL group, we are interested in potential chemical differences between the allosteric and background set. Interestingly, the allosteric modulators appear to form a subset of the background set, rather than that they are distinct from the background set. We have calculated a large number of descriptors and compared the sets (median values, but also histograms; all available on the FTP). We observe that allosteric modulator molecules tend to be smaller, more lipophilic and more rigid. Although there is understandably a large variance over the diverse targets included in the set. Shown here is the rigidity index calculated over the full sets (L0), but when the target selection becomes more concise, the differences become more distinct.



Bioactivity
Likewise we observe differences between our allosteric subset and the background set with regard to bioactivity. While 'allosteric modulation' is a very diverse concept, in which the specific manner wherein the protein is influenced by the small molecule differs per protein - ligand pair, we do observe some general differences. From our data it appears that allosteric modulators bind with a lower affinity (on average) but similar ligand efficiency (on average) when compared to our background set. In the paper we provide a more extensive discussion on this observation and we would again refer the reader given the limited space here.

Classification models
Built on the dataset we have created allosteric classifier models that can predict if an interaction is likely allosteric or not. We have tried this on the full dataset, but also on lower levels (restricting the data to e.g. Class A GPCRs). We find that we can train predictive models that gain in quality if we have a more concise dataset (eliminating some of the inter-target variation). In the paper we provide case studies on HIV Reverse Transcriptase, the adenosine receptors (family), and protein Kinase B. Here the model performance for class A GPCRs (full L2 tgt class) is shown. Note that rigidity, number of sp3 carbons, Polar Solvent Accessible Surface (normalized), and rotatable bonds fraction are most important for model fit.


All data is ChEMBL and hence can be freely downloaded and used. Please let us know if you find any errors or misclassifications as we will correct them (crowd curation).

Anna, jpo, and Gerard

%T Chemical, Target, and Bioactive Properties of Allosteric Modulation
%A G.J.P. van Westen
%A A. Gaulton
%A J.P. Overington
%J PLoS. Comput. Biol.
%D 2014
%V 10
%O doi:10.1371/journal.pcbi.1003559

Comments

Popular posts from this blog

SureChEMBL Available Now

Followers of the ChEMBL group's activities and this blog will be aware of our involvement in the migration of the previously commercially available SureChem chemistry patent system, to a new, free-for-all system, known as SureChEMBL. Today we are very pleased to announce that the migration process is complete and the SureChEMBL website is now online. SureChEMBL provides the research community with the ability to search the patent literature using Lucene-based keyword queries and, much more importantly, chemistry-based queries. If you are not familiar with SureChEMBL, we recommend you review the content of these earlier blogposts here and here . SureChEMBL is a live system, which is continuously extracting chemical entities from the patent literature. The time it takes for a new chemical in the patent literature to become searchable in the SureChEMBL system is 1-2 days (WO patents can sometimes take a bit longer due to an additional reprocessing step). At time of writi

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

ChEMBL & SureChEMBL anniversary symposium

  In 2024 we celebrate the 15th anniversary of the first public release of the ChEMBL database as well as the 10th anniversary of SureChEMBL. To recognise this important landmark we are organising a two-day symposium to celebrate the work achieved by ChEMBL and SureChEMBL, and look forward to its future.   Save the date for the ChEMBL 15 Year Symposium October 1-2, 2024     Day one will consist of four workshops, a basic ChEMBL drug design workshop; an advanced ChEMBL workshop (EUbOPEN community workshop); a ChEMBL data deposition workshop; and a SureChEMBL workshop. Day two will consist of a series of talks from invited speakers, a few poster flash talks, a local nature walk, as well as celebratory cake. During the breaks, the poster session will be a great opportunity to catch up with other users and collaborators of the ChEMBL resources and chat to colleagues, co-workers and others to find out more about how the database is being used. Lunch and refreshments will be pro

ChEMBL 34 is out!

We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.

RDKit, C++ and Jupyter Notebook

Fancy playing with RDKit C++ API without needing to set up a C++ project and compile it? But wait... isn't C++ a compiled programming language? How this can be even possible? Thanks to Cling (CERN's C++ interpreter) and xeus-cling jupyter kernel is possible to use C++ as an intepreted language inside a jupyter notebook! We prepared a simple notebook showing few examples of RDKit functionalities and a docker image in case you want to run it. With the single requirement of docker being installed in your computer you'll be able to easily run the examples following the three steps below: docker pull eloyfelix/rdkit_jupyter_cling docker run -d -p 9999:9999 eloyfelix/rdkit_jupyter_cling open  http://localhost:9999/notebooks/rdkit_cling.ipynb  in a browser